Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $5.90. The biopharmaceutical company, which focuses on iPSC-derived cellular immunotherapies, reported quarterly revenue of $2.08 million and an adjusted loss of $0.25 per share, matching analyst expectations. Institutional investors hold a significant 97.54% stake in the company, with recent activity from BlackRock and Johnson & Johnson.
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE
Dimensional Fund Advisors LP significantly reduced its stake in Fate Therapeutics, Inc. by 44.0% in the first quarter, selling 693,688 shares and retaining 883,790 shares valued at approximately $1.06 million. Despite this, institutional investors and hedge funds still collectively own 97.54% of the company. Fate Therapeutics reported an EPS of -$0.25, meeting analyst expectations, with revenue exceeding forecasts, though the company remains unprofitable and analysts project a full-year EPS loss of $1.04.
Fate Therapeutics (FATE) Stock Drifts Higher Despite Persistent Cash Burn
Fate Therapeutics (FATE) stock saw a modest increase despite reporting significant losses in Q2 2026, with a net loss of US$30 million. While the company's revenue slightly increased year-over-year and losses narrowed, funding risk remains due to its substantial cash burn. Bullish sentiment is supported by positive early clinical data for FT819, but skeptics point to the ongoing losses and recent stock price declines.
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis
Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN trial for FT819, an off-the-shelf CAR T-cell therapy aimed at treating refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial, which plans to enroll approximately 53 patients, will evaluate FT819's efficacy and safety, with complete renal response at Week 26 as the primary endpoint. This study benefits from FDA's RMAT designation and participation in the CMC Development and Readiness Pilot program, indicating a potential for an accelerated regulatory path.
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis
Fate Therapeutics has started RECLAIM-LN, a Phase 2 registrational trial for its off-the-shelf CAR T-cell therapy FT819, targeting refractory lupus nephritis. This follows positive Phase 1 safety and efficacy data. The trial, developed with FDA interaction, aims to enroll 53 patients, with preliminary data indicating significant improvements in disease activity and a favorable safety profile.
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)
Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share and revenues of $2.08 million, exceeding the $1.37 million consensus. Despite an overall "Hold" rating from other analysts, the stock has a consensus price target of $5.38.
Fate Therapeutics doses first patient in FT819 lupus trial
Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN clinical trial for FT819, a treatment for refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial aims to enroll approximately 53 patients with Class III or IV lupus nephritis, expecting to complete enrollment by the first half of 2028. FT819, an off-the-shelf CAR T-cell product, has received Regenerative Medicine Advanced Therapy designation from the FDA, with preliminary Phase 1 data showing promising improvements in disease activity.
Fate Therapeutics' First FT819 Patient Went Home Same Day
Fate Therapeutics has initiated its RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, in patients with lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, with the study aiming to enroll approximately 53 patients by the first half of 2028. This trial leverages RMAT designation and FDA CMC pilot program participation for a potential accelerated regulatory pathway, building on favorable safety and efficacy observations from earlier studies.
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated its potentially registrational Phase 2 RECLAIM-LN clinical trial for FT819, an off-the-shelf CAR T-cell therapy, to treat refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The first patient has been dosed in an outpatient setting, and the study aims to enroll approximately 53 patients, with results expected by the first half of 2028. This trial leverages the FDA's RMAT designation and CMC Development and Readiness Pilot program, building on promising Phase 1 safety and efficacy data.
Fate Therapeutics earnings beat by $0.02, revenue topped estimates
Fate Therapeutics (NASDAQ: FATE) announced second-quarter EPS of $-0.250, surpassing analyst estimates by $0.02, and reported revenue of $2.08 million, exceeding the consensus of $1.29 million. The company's stock has seen significant growth, rising 43.590% in the last three months and 131.190% over the past year. InvestingPro rates Fate Therapeutics' financial health as "fair performance."
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5
Wells Fargo has increased its target price for FATE Therapeutics, Inc. (FATE.O) to $3.5 from $2.5. This update was reported by Reuters on August 14, 2026. The article is a brief financial news alert.
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com
This article announces the filing of a Form 8K by Fate Therapeutics Inc. for August 13. It includes the company's stock symbol FATE and notes a 1.98% increase. The content is a brief financial update presented by Investing.com.
Fate Therapeutics: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Fate Therapeutics (FATE) for the second quarter. It indicates that the company reported its Q2 results, though specific financial details are not included in the provided content. The article itself is very short and does not offer any further analysis or data.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its second quarter 2026 financial results, highlighting the initiation of its Phase 2 RECLAIM-LN trial for FT819 in lupus nephritis and the FDA clearance of the FT839 IND application for autoimmune disease. The company reported a cash runway extending into 2028 and presented preliminary clinical data for FT819 in systemic sclerosis and FT836 in colorectal cancer. Additionally, Laura Hamill was appointed to the Board of Directors, bringing commercial expertise as the company moves towards later-stage development.
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Fate Therapeutics (NASDAQ:FATE) reported its quarterly earnings, exceeding analyst expectations with an adjusted loss of $0.25 per share, $0.02 better than estimates, and revenue of $2.08 million against a consensus of $1.37 million. Despite beating expectations, the biopharmaceutical company remains unprofitable, showing a negative net margin of 2,056.79% and a negative return on equity of 58.89%. Analysts have a mixed sentiment, with an average "Hold" rating and a consensus price target of $6.00, while institutional investors hold a significant majority of the outstanding shares.
Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M
Fate Therapeutics announced its Q2 2026 financial results, reporting $2.1 million in revenue and a net loss of $30.2 million. The company ended the quarter with $153.8 million in cash and expects its cash runway to extend into 2028. Additionally, Fate Therapeutics highlighted significant clinical advancements in its iPSC-derived off-the-shelf CAR T programs, including progress in trials for lupus nephritis and other autoimmune indications.
Fate Therapeutics: Q2 Earnings Snapshot
Fate Therapeutics (FATE) reported a Q2 GAAP loss of $0.65 per share, which was narrower than the prior year's loss of $0.69 per share. While the company did not generate revenue in the quarter, the results indicate a slight improvement in its financial performance compared to the same period last year.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its Q2 2026 financial results, highlighting significant clinical milestones including the dosing of the first lupus nephritis patient in its RECLAIM-LN trial for FT819 with same-day discharge. The company also reported FDA clearance for FT839's IND application for an autoimmune disease trial and preliminary positive data for FT819 in SLE and systemic sclerosis. Despite a sequential decrease in cash, Fate Therapeutics projects its cash runway will extend into 2028.
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com
This article from Investing.com reports on the filing of a Form 8K by Fate Therapeutics Inc. for August 13. The brief notice indicates a regulatory filing has been made by the company. It includes no further details about the content of the Form 8K, simply confirming its existence.
Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss
Fate Therapeutics (FATE) reported a second-quarter 2026 net loss of $30.2 million on $2.1 million in revenue. The company initiated a Phase 2 trial for lupus nephritis and received FDA clearance for another CAR T-cell product candidate, while its cash reserves declined by $21 million during the quarter. Insider trading shows sales by executives, and institutional investors have mixed positions.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its second-quarter 2026 financial results and provided business updates. Key highlights include the dosing of the first lupus nephritis patient in its RECLAIM-LN trial for FT819, FDA clearance for the FT839 IND application for autoimmune disease, and preliminary positive clinical data for FT819 in systemic sclerosis. The company also reported a cash runway extending into 2028 and the appointment of Laura Hamill to its Board of Directors.
Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE
Renaissance Technologies LLC has increased its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 26% during the first quarter, now owning 2.97 million shares valued at approximately $3.57 million. Other institutional investors have also adjusted their holdings, contributing to institutional ownership of 97.54% of the company. Despite mixed analyst sentiment and a "Hold" rating, the biopharmaceutical company reported a first-quarter loss of $0.26 per share, beating estimates, though revenue fell short of forecasts.
Don't Ignore The Insider Selling In Fate Therapeutics
Fate Therapeutics (NASDAQ: FATE) recently saw its President, Bahram Valamehr, sell US$108k worth of stock, representing a 23% reduction in his holdings. This sale, at a price slightly below the current market value, is the largest insider sale in the past year for the company. Coupled with a low insider ownership of 1.5%, this activity suggests caution regarding the stock, as there has been no insider buying in the last three months or the past year.
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc is anticipated to report a loss of 27 cents per share. This information comes from a Reuters earnings preview available on TradingView, which cites Refinitiv as the source for this financial projection.
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history
Fate Therapeutics, Inc. (FATE) is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune disorders. The article provides current stock information, including a price of $2.7808 with a 12.45% increase at close, and a company overview highlighting its various CAR-targeted NK and T-cell product candidates in preclinical and clinical stages. Financial highlights and analyst insights, including a "Buy" rating from HC Wainwright & Co. with a $7 price target, are also presented.
Don't Ignore The Insider Selling In Fate Therapeutics
The President of Fate Therapeutics, Bahram Valamehr, recently sold US$108k worth of stock, representing a 23% reduction in his holdings. This marks the largest insider sale in the last twelve months, and there has been no insider buying during the same period. With relatively low insider ownership, the article suggests caution regarding the stock.
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history
This article provides a comprehensive overview of Fate Therapeutics, Inc. (FATE) stock, including its current price, market performance, and financial data. It details the company's focus on developing programmed cellular immunotherapies for cancer and immune disorders, highlighting its key product candidates and collaborations. The report also includes analyst insights, earnings trends, and comparative metrics with similar biotechnology companies.
Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History
This article provides a detailed financial overview of Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company. It includes current stock price, historical data, performance metrics against the S&P 500, and analyst insights. The company specializes in developing programmed cellular immunotherapies for cancer and immune disorders.
Fate Therapeutics (FATE) CEO sells 43,947 shares to cover RSU tax
Fate Therapeutics (FATE) CEO Bahram Valamehr sold 43,947 shares of common stock on August 4, 2026, at a weighted average price of $2.4598 per share. This sale was a mandatory "sell-to-cover" transaction to meet tax withholding obligations arising from the vesting of 75,000 Restricted Stock Units (RSUs). Following the transaction, Valamehr directly holds 591,815 shares of Fate Therapeutics common stock.
Fate Therapeutics (NASDAQ: FATE) CLO sells 38,800 shares to cover taxes
Fate Therapeutics' Chief Legal and Compliance Officer, Cindy Tahl, sold 38,800 shares of common stock on August 4, 2026, at a weighted average price of $2.4589 per share. This sale was a "sell-to-cover" transaction to meet tax withholding obligations tied to the vesting of 75,000 RSUs and was not discretionary. Following the transaction, Tahl directly holds 589,355 shares of Fate Therapeutics common stock.
Fate Therapeutics (FATE) to Release Quarterly Earnings on Tuesday
Fate Therapeutics (NASDAQ:FATE) is scheduled to release its Q2 2026 earnings before the market opens on Tuesday, August 11th. Analysts anticipate a loss of $0.28 per share and revenue of $1.37 million. Despite beating EPS expectations in the previous quarter, the company remains heavily unprofitable with a negative net margin exceeding 2,000%.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced new employee inducement awards on August 1, 2026, consisting of non-qualified stock options for 37,300 shares and restricted stock units (RSUs) for 45,300 shares to newly-hired non-executive employees. These awards were granted under the Company’s Amended and Restated Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to incentivize their employment. The options and RSUs will vest over four years, subject to continuous employment.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. (NASDAQ: FATE) announced new employee inducement awards on August 1, 2026, comprising non-qualified stock options for 37,300 shares to one new non-executive employee and restricted stock units (RSUs) for 45,300 shares to two new non-executive employees. These grants, approved by the Compensation Committee, were made under the Company’s Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, subject to continuous employment.
FATE (FATE) holder discloses 43,947-share potential sale and prior trade
Bahram Valamehr has filed a Form 144 notice indicating a potential sale of 43,947 common shares of FATE Therapeutics Inc. These shares are associated with restricted stock vesting on August 3, 2026, and will be traded on NASDAQ through Fidelity Brokerage Services LLC. The filing also reveals a prior sale of 28,946 common shares on May 20, 2026, which generated $54,482.16.
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Fate Therapeutics Inc (FATE), noting its current valuation score of 7.83, which ranks it 188th out of 384 companies in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.17, while also stating that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Irenic Capital Management LP Purchases Shares of 878,055 Fate Therapeutics, Inc. $FATE
Irenic Capital Management LP acquired 878,055 shares of Fate Therapeutics, Inc. ($FATE) in the first quarter, a stake valued at approximately $1.05 million. Fate Therapeutics, a clinical-stage biopharmaceutical company, reported a quarterly loss that beat estimates but revenue that fell short. The company currently has a consensus "Hold" rating from analysts with an average price target of $5.12.
Fate Therapeutics Inc (FATE) Institutional Confidence
The article analyzes the institutional confidence in Fate Therapeutics Inc (FATE), noting its current institutional shareholding score of 7.00, which ranks 80 out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 79.47%, representing a quarter-over-quarter decrease of 34.82%. Bill Nygren | OAKMX is identified as the largest institutional shareholder, holding 5.22 million shares.
FATE|Fate Therapeutics Inc|Price:2.325|Chg%:-0.105
Fate Therapeutics Inc (FATE) is a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies. The stock is currently trading at 2.360 USD, with analysts rating it a "Buy" and a target price of 5.588, suggesting a significant upside. Despite weak short-term performance, the company's fundamentals are stable, growth potential is significant, and institutional ownership is high.
Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis
Fate Therapeutics Inc (FATE) currently holds a financial score of 5.71, ranking 326 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The company's latest quarterly revenue was $1.30 million, a 20.26% decrease year-over-year, and its net profit also saw a 17.03% year-over-year decline. Key financial metrics such as cash and cash equivalents, total assets, operating profit, and free cash flow have not been fully disclosed by the company.
Cost of goods sold of Fate Therapeutics, Inc. – HAM:F6T
This article displays a financial page for Fate Therapeutics, Inc. (HAM:F6T) on TradingView, specifically focusing on the company's "Cost of goods sold." The page confirms the market is closed, shows no recent trades, and provides standard navigation for financial data, news, and community features related to the stock.
Cash flow from operating activities of Fate Therapeutics, Inc. – HAM:F6T
This article focuses on the cash flow from operating activities for Fate Therapeutics, Inc. (HAM:F6T), a biotechnology company listed on the Hamburg Stock Exchange. It appears to be a financial data presentation page from TradingView, indicating no trades and a closed market. The content provides a general overview of the company's financial data as part of a larger financial analysis platform.
Tangible book value per share of Fate Therapeutics, Inc. – HAM:F6T
This article provides a financial metric, the tangible book value per share, for Fate Therapeutics, Inc. (HAM:F6T). It appears to be a stub or a data point from a financial platform like TradingView, lacking detailed analysis or historical data within the provided content. The information is presented within a framework of market data and financial tools.
Operating expenses (excl. COGS) of Fate Therapeutics, Inc. – HAM:F6T
This page from TradingView provides financial information for Fate Therapeutics, Inc. (HAM:F6T), specifically focusing on its operating expenses excluding the cost of goods sold (COGS). It appears to be a financial data portal displaying key metrics for the company.
Fate Therapeutics Inc (FATE) Cash Flow
This article provides a detailed cash flow statement for Fate Therapeutics Inc (FATE), including operating, investing, and financing cash flows presented quarterly and annually. It also offers explanations of these cash flow types and answers frequently asked questions regarding FATE's cash flow performance, such as its operating cash flow of -106.08M in fiscal 2025 and a free cash flow of -112.04M in the latest quarter.
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Fate Therapeutics Inc (FATE), outlining major institutional holders and their proportion of shares. It presents data on top shareholders like Redmile Group, LLC, ARK Investment Management LLC, and BlackRock, along with a breakdown of shareholder types and institutional shareholding trends over several quarters. The report also lists related ETFs that hold FATE shares.
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fate Therapeutics Inc (FATE) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no dividend data. The page also includes current stock performance metrics like market capitalization and stock price.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages
Fate Therapeutics (NASDAQ:FATE) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $5.13. Analyst actions have been mixed, and while the company reported a narrower-than-expected quarterly loss of ($0.26) per share, revenue missed estimates. An insider sale occurred in May, and institutional investors retain significant holdings.
Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE
Fate Therapeutics, Inc. (NASDAQ: FATE) generated $6.65 million USD in revenue last year, primarily from its Cellular Immunotherapies segment. This marks a decrease from the $13.63 million USD reported the previous year. The United States was the sole geographic contributor to this revenue.
BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc
BlackRock, Inc. has significantly reduced its stake in Fate Therapeutics Inc by selling 7,874,330 shares at $2.70 per share, leaving them with 2,194,284 shares. This move suggests a strategic reevaluation of its investment in the biopharmaceutical company, which is currently considered significantly overvalued despite its innovative pipeline. Fate Therapeutics faces challenges with a low GF Score, negative ROE, and poor financial strength, although it shows positive EBITDA growth.
FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions
The FDA has approved the initiation of clinical testing for Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy, FT839, for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans a basket Phase 1/2 trial to evaluate FT839, which is designed to target multiple disease-driving immune cells (CD19 and CD38), in combination with standard treatments. This dual-CAR T-cell therapy aims to offer an accessible, on-demand treatment option that overcomes limitations of current cell therapies.
